GET DAILY SIGNALSWhy Is SOPHiA GENETICS (SOPH) Stock Down -10.69% Today?
Key Takeaways
- SOPHiA GENETICS shares fell roughly 10.69% intraday on Tuesday, dropping from a prior close of $7.11 to about $6.35.
- The primary catalyst was a third-quarter earnings release that showed a wider-than-expected loss despite strong revenue growth.
- The company reported Q3 2026 EPS of -$0.24, missing the consensus estimate of approximately -$0.18 by $0.06.
- Revenue rose 25% year over year to $24.3 million, and management reaffirmed its outlook at the upper end of its full-year guidance range.
- Broader sentiment around high-growth, pre-profitability healthcare-technology names added to the selling pressure.
- Traders are now watching how shares absorb the earnings-driven move and whether the post-earnings weakness stabilizes.
- For more detail on analyst expectations and valuation metrics, explore Price Targets, Earnings, and Forecast pages for SOPH.
- Discover the strongest AI-driven trading strategies currently in the market by visiting Trending AI Robots.
Opening Summary
SOPHiA GENETICS SA (SOPH), the Switzerland-based, AI-native healthcare technology company behind the SOPHiA DDM™ platform for genomic and multimodal data analysis, saw its shares slide sharply on Tuesday. The stock fell approximately 10.69% intraday, trading near $6.35 compared with a prior closing price of $7.11. The move came as investors digested the company's third-quarter 2026 results, which delivered robust top-line growth but a wider loss per share than Wall Street had anticipated, prompting a sell-off in the shares.
Earnings Results: Strong Revenue, Wider Loss
The dominant driver behind the decline was the company's Q3 2026 earnings report, released before the opening bell. SOPH posted revenue of $24.3 million, up 25% year over year (26% on a constant-currency basis), reflecting continued adoption of its platform across hospital, laboratory, and biopharma customers. Platform analysis volume reached a record 118,000 analyses in the quarter, a 19% year-over-year increase.
However, the bottom line fell short of expectations. The company reported a net loss of $20.3 million, or -$0.24 per share, versus analyst estimates of roughly -$0.18 per share — a miss of about $0.06. While revenue was broadly in line with consensus, the wider loss underscored the market's sensitivity to profitability progress in pre-earnings technology companies, and shares reacted negatively.
Guidance and Profitability Outlook
Despite the EPS miss, management struck an optimistic tone on its conference call. Executives said they now expect full-year 2026 revenue to land at the upper end of the previously issued guidance range of $94 million to $96 million. The company also highlighted a 31% year-over-year improvement in adjusted EBITDA and noted that nearly 60% of incremental revenue was flowing to the bottom line, signaling improving operating leverage.
Even so, SOPH remains unprofitable, and management reiterated that a crossover to positive adjusted EBITDA is not expected until the second half of next year. For a stock trading on future growth expectations, the extended timeline to profitability appeared to weigh on sentiment during the session.
Market Context and Trading Activity
The earnings-driven move occurred within a broader environment of caution around small- and mid-cap healthcare and genomics names, where investors have increasingly favored demonstrated profitability over pure revenue growth. Selling pressure in SOPH was consistent with a market that rewarded top-line momentum but penalized a steeper-than-expected loss.
Trading activity reflected elevated volatility, with the stock trading well below its recent range and breaking below the $7.00 level that had provided support over the prior sessions. The decline also stood out against the stock's longer-term trend, which had shown significant appreciation over the trailing twelve months, suggesting the session's move was primarily a reaction to the earnings print rather than a shift in the company's fundamental trajectory.
What Comes Next for SOPH
Looking ahead, investors will focus on whether SOPH can sustain its momentum in high-growth segments such as liquid biopsy, solid tumor testing, and biopharma collaborations. Recent commercial wins, including companion-diagnostic programs and a collaboration with a top-10 biopharma company, point to a broadening revenue pipeline, but execution and the pace of margin improvement will remain key areas of scrutiny.
Risks include foreign-exchange headwinds on an international revenue base, the timing of new customer ramps, and the company's path to profitability. While management reaffirmed confidence in its outlook, the market's reaction highlights how sensitive the stock remains to earnings quality and the trajectory toward positive adjusted EBITDA.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a way to explore data-driven approaches to the markets. Visit Trending AI Robots to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SOPH's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SOPH turned positive on October 26, 2026. Looking at past instances where SOPH's MACD turned positive, the stock continued to rise in 49 of 54 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SOPH's RSI Oscillator exited the oversold zone, 14 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on SOPH as a result. In 104 of 119 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SOPH advanced for three days, in 205 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SOPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
SOPH moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SOPH crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for SOPH entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.282) is normal, around the industry mean (4.699). P/E Ratio (-6.129) is within average values for comparable stocks, (13.248). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.452) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. SOPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Do You Understand Tax Returns: Importance, Retention, and Deductions?
AI Trading Agents: Top Performers for Down Markets as of May 28, 2025
4 Key Points: Day vs. Swing Trading
The 1999 Melt-Up Forecast: Why the AI Bubble Has Not Peaked and the Biggest Gains in the S&P 500 May Still Lie Ahead
AI Trading Agent Reports 2.62 Profit Factor in NVDA and USAR Trading Results
General Information
Industry ServicestotheHealthIndustry
Advertisement